Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTMarketBeatWed, August 5, 2026 at 1:04 AM GMT+2 6 min readKey PointsInterested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better.Cumberland completed the sale of its branded U.S. commercial portfolio to Apotex for $100 million upfront, with up to $21 million in additional inventory, transition and milestone payments. The company also returned approximately $22 million to shareholders through a $1.50-per-share special dividend.The transaction shifts Cumberland's focus to an innovation-driven biopharmaceutical model centered on ifetroban. The company expects its remaining cash to fund operations for more than five years while advancing programs in Duchenne muscular dystrophy, systemic sclerosis and idiopathic pulmonary fibrosis.Key 2026 catalysts include systemic sclerosis top-line results, interim efficacy data from the pulmonary fibrosis study and further FDA discussions on Duchenne muscular dystrophy. Cumberland also reported encouraging early efficacy signals from an ifetroban oncology collaboration with Vanderbilt.Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.The transaction, which closed July 1, delivered $100 million in cash at closing. Cumberland said it also expects to receive $11 million for inventory and transition payments over the next 12 months, as well as a potential $10 million milestone payment. The company estimated net proceeds from the transaction of approximately $108 million, after taxes of less than $1 million.→